Transplant News and Research

RSS

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 people in the United States were living with a kidney transplant.

31 May 2010

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

Targeted Genetics Corporation announced that its partner, Celladon Corporation, presented full data today that show the first Phase II trial with MYDICAR® for the treatment of advanced heart failure has met its primary safety and efficacy endpoints, as prospectively defined in the Phase II trial protocol.

31 May 2010

RNAi therapy shuts down gene critical to RSV, prevents virus replication

John DeVincenzo, MD, professor and researcher in the Departments of Pediatrics and Molecular Sciences at the University of Tennessee Health Science Center (UTHSC), has proven for the first time that a totally new concept in drug design can be used to treat human disease. Dr. DeVincenzo, who also serves as a children's infectious diseases specialist at Le Bonheur Children's Hospital, conducted his study at the Children's Foundation Research Center, a UT Health Science Center partner located at Le Bonheur.

29 May 2010

New, non-controversial source of stem cells can form heart muscle cells, repair heart damage

A new and non-controversial source of stem cells can form heart muscle cells and help repair heart damage, according to results of preliminary lab tests reported in Circulation Research: Journal of the American Heart Association.

29 May 2010

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

A group of "color-coded" laboratory mice are providing researchers with a novel way of tracking T-cells, enabling them to visualize and monitor the cellular immune responses of transplanted tissue in real time. The new imaging system is described in the June issue of Nature Medicine, which appears on-line this week.

28 May 2010

Advocates urge Congress to reauthorize C.W. Bill Young Cell Transplantation Program and NCBI

More than 60 adult donors, transplant recipients, family members and medical professionals from 25 states met with lawmakers and staff on Capitol Hill today to urge Congress for increased federal funding to grow and diversify the national registry of adult donors and publicly available cord blood units as part of the C.W. Bill Young Transplantation Program and the National Cord Blood Inventory.

28 May 2010

New study provides cause-and-effect link between immune system cells and mental illness

A Nobel Prize-winning University of Utah geneticist discovered that bone marrow transplants cure mutant mice who pull out their hair compulsively. The study provides the first cause-and-effect link between immune system cells and mental illness, and points toward eventual new psychiatric treatments.

28 May 2010

New surgical procedure improves survival in infants with severely underdeveloped hearts

Pediatric researchers report that a recently introduced surgical procedure offers infants with severely underdeveloped hearts a better chance at surviving during their first year of life in comparison to the standard surgery.

28 May 2010

State-of-the-art heart pump lowers risk for infection in end-stage cardiac patients: Researchers

A state-of-the-art heart pump recently approved for use in end-stage cardiac patients has a significantly lower risk for infection than an earlier model of the device, according to researchers at Henry Ford Hospital in Detroit.

28 May 2010

Bone marrow transplant cures excessive pathological grooming behavior in mice

Scientists earlier found that mice missing one of a group of core developmental genes known as the Hox genes developed an odd and rather unexpected pathology: the mutant animals groomed themselves compulsively to the point that they were removing their own hair and leaving self-inflicted open sores on their skin. Now, they've found a surprising connection between the Hoxb8 gene and the behavior that looks an awful lot like that of people with an obsessive compulsive spectrum disorder (OCD).

28 May 2010

HeartMate II left ventricular assist device also improves right side heart function

A state-of-the-art heart pump, designed to maintain a continuous flow of blood in end-stage cardiac patients with damage to the left side of the heart, also improves function on the right side of the heart, according to researchers at Henry Ford Hospital's Heart and Vascular Institute.

27 May 2010

Leading stem cell scientists to discuss on stem cell clinical trials for ALS and heart attack patients

The first Cedars-Sinai Regenerative Medicine Scientific Symposium, dedicated to furthering our ability to bring stem cell therapies from the laboratory to the patient bedside. The conference, led by Clive Svendsen, Ph.D., and Eduardo Marb-n, M.D., Ph.D., will highlight the most recent developments in leading-edge stem cell research and treatments for brain and heart diseases.

27 May 2010

Largest clinical trial to compare surgical treatments for congenital heart disease

27 May 2010

UCI scientists create eight-layer, early-stage retina from human embryonic stem cells

UC Irvine scientists have created an eight-layer, early-stage retina from human embryonic stem cells, the first three-dimensional tissue structure to be made from stem cells.

27 May 2010

Patients with transformed lymphoma show positive response to lenalidomide: Research

New research illustrates that some patients with transformed lymphoma showed "remarkable" response to lenalidomide, an oral drug with few side effects.

27 May 2010

Gentium first-quarter net loss decreases to EUR 0.03 million

Gentium S.p.A. today reported financial results for the quarter ended March 31, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP).

26 May 2010

Lyophilized heparin demonstrates better ability to preserve cord blood stem cells than CPD: Study

Lyophilized heparin, a proprietary anticoagulant developed specifically for cord blood collection, demonstrated a better ability to preserve the number of viable cells over a longer period of time than a commonly-used anticoagulant, citrate phosphate dextrose, according to a study presented today at the International Society for Cellular Therapy Annual Meeting.

26 May 2010

SCID added to the core panel of 29 genetic disorders

On May 21, 2010, Kathleen Sebelius, Secretary of Health and Human Services announced the addition of Severe Combined Immunodeficiency -- commonly known as bubble boy disease -- to the core panel of 29 genetic disorders -- as part of her recommendation to adopt the national Recommended Uniform Screening Panel.

26 May 2010

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.

25 May 2010

Transplant News and Research

Researchers identify pattern of gene expression in kidney transplant recipients who don't need anti-rejection drugs

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Targeted Genetics's partner Celladon presents Phase II trial data with MYDICAR at Heart Failure Congress 2010

RNAi therapy shuts down gene critical to RSV, prevents virus replication

New, non-controversial source of stem cells can form heart muscle cells, repair heart damage

Novel imaging system helps visualize and monitor cellular immune responses of transplanted tissue in real time

Advocates urge Congress to reauthorize C.W. Bill Young Cell Transplantation Program and NCBI

New study provides cause-and-effect link between immune system cells and mental illness

New surgical procedure improves survival in infants with severely underdeveloped hearts

State-of-the-art heart pump lowers risk for infection in end-stage cardiac patients: Researchers

Bone marrow transplant cures excessive pathological grooming behavior in mice

HeartMate II left ventricular assist device also improves right side heart function

Leading stem cell scientists to discuss on stem cell clinical trials for ALS and heart attack patients

Largest clinical trial to compare surgical treatments for congenital heart disease

UCI scientists create eight-layer, early-stage retina from human embryonic stem cells

Patients with transformed lymphoma show positive response to lenalidomide: Research

Gentium first-quarter net loss decreases to EUR 0.03 million

Lyophilized heparin demonstrates better ability to preserve cord blood stem cells than CPD: Study

SCID added to the core panel of 29 genetic disorders

Genzyme's Lumizyme for Pompe disease receives FDA marketing approval

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News